These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19837058)

  • 21. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
    Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
    Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New development in the treatment of psoriasis--infliximab.
    Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE; Gurske J
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of TNF-α antagonists on the quality of life in selected skin diseases.
    Gisondi P; Girolomoni G
    G Ital Dermatol Venereol; 2013 Jun; 148(3):243-8. PubMed ID: 23670060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ].
    Puig Sanz L; Sáez E; Lozano MJ; Bordas X; Carrascosa JM; Gallardo F; Luelmo J; Sánchez-Regaña M; Alsina M; García-Patos V;
    Actas Dermosifiliogr; 2009 Mar; 100(2):103-12. PubMed ID: 19445874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of psoriasis: focus on clinic-based management with infliximab.
    de Eusebio E; Armario-Hita JC; de Miquel VA
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S5-16. PubMed ID: 24777571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The psoriatic patient profile for infliximab.
    Gisondi P; Malara G; Ardigò M
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1445-51. PubMed ID: 22288305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab treatment of psoriasis in supervised infusion centers: case management experience.
    Campos Muñoz L; de Unamuno Bustos B; Herranz Pinto P; El Ahmed HH; Ruiz-Villaverde R; Taberner Ferrer R
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S17-24. PubMed ID: 24777572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Infliximab: patients selection].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():23-9. PubMed ID: 19080988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
    Sockolov ME; Alikhan A; Zargari O
    J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab and nephrotic syndrome.
    Chin G; Luxton G; Harvey JM
    Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Up-date on the use of infliximab in dermatology. Introduction].
    Sánchez-Carazo J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
    [No Abstract]   [Full Text] [Related]  

  • 38. Approach to managing patients with nail psoriasis.
    Reich K
    J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ten years of infliximab: insights from clinical trials in rheumatoid arthritis.
    Smolen JS
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S5-9. PubMed ID: 19843471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.